ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable development of acquired resistance limits its efficacy....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Pharmacol
Main Authors: Zhao, Hongbo, Huang, Yutang, Shi, Jingjing, Dai, Yi, Wu, Lanxiang, Zhou, Honghao
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2018
Assuntos:
Pharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6256088/
https://ncbi.nlm.nih.gov/pubmed/30515095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.01312
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares